Aardvark Therapeutics Securities Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of MiNK Therapeutics, Inc. (NASDAQ: AARD) securities of the October 13, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that in the Registration Statement issued in connection with Aardvark's February 13, 2025 initial public offering and throughout the Class Period (February 13, 2025 to May 14, 2026), defendants made materially false and misleading statements and failed to disclose material adverse facts about Aardvark's business, operations, and prospects. Specifically, defendants allegedly failed to disclose that ARD-101 was less safe than represented, and that its clinical, regulatory, and commercial prospects were overstated. When the true details entered the market, investors suffered damages. The class action has already been filed, and investors who purchased Aardvark securities may be entitled to compensation without out-of-pocket fees through a contingency fee arrangement.